Trends in smoking-related diseases

Jt, Hays; Dale, LC; Rd, Hurt; It, Croghan

doi:10.3810/pgm.1998.12.389

Cited by 34 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies (8, 10, 18) have demonstrated that smoking is a major risk factor for many respiratory diseases and symptoms with a dose-response relationship. This supports that smoking is an important factor for chronic sputum irrespective of geographical location as well as other smoking-related diseases (10, 19, 20), and that smoking cessation should be encouraged in subjects with chronic sputum to relieve their symptoms.…”

Section: Discussionsupporting

confidence: 62%

Prevalence of Chronic Sputum and Associated Factors in Korean Adults

Lee

Kim

et al. 2014

J Korean Med Sci

View full text Add to dashboard Cite

Chronic sputum is a troublesome symptom in many respiratory diseases. The prevalence of chronic sputum varies from 1.2% to 13% according to the country. The purpose of this study was to estimate the prevalence of chronic sputum and to find its associated factors in a general Korean population. We analyzed the data of the Korea National Health and Nutrition Examination Survey 2010 and 2011. A total number of 6,783 subjects aged 40 yr or more were enrolled in this study with 3,002 men and 3,781 women. As a result, the prevalence of chronic sputum was 6.3% (n=430). Significant risk factors for chronic sputum by multivariate analysis were: age (≥70 yr) (odds ratio [OR], 1.954; 95% confidence interval [CI], 1.308-2.917), current smoking (OR, 4.496; 95% CI, 3.001-6.734), chronic obstructive pulmonary disease (COPD) (OR, 1.483; 95% CI, 1.090-2.018), and tuberculosis (OR, 1.959; 95% CI, 1.307-2.938). In conclusion, the prevalence of chronic sputum in Korea was in the intermediate range compared with other countries. Smoking is a preventable risk factor identified in this study, and major respiratory diseases, such as COPD and tuberculosis, should be considered in subjects with chronic sputum.Graphical Abstract

show abstract

Section: Discussionsupporting

confidence: 62%

Prevalence of Chronic Sputum and Associated Factors in Korean Adults

Lee

Kim

et al. 2014

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…Quitting may also have been more difficult for Reservists and National Guard members who faced possible redeployment and ongoing service/stress. Consistent with previous reports, current smoking was related to reduced mental and physical quality of life (Hayes, Dale, Hurt, & Croghan, 1999) and increased report of probable alcohol misuse (Calhoun, Elter, Jones, Kudler, & Straits-Troster, 2008). These findings underscore the continued need to address comorbid mental health and substance use concerns in veterans.…”

Section: Discussionsupporting

confidence: 87%

Characteristics and Correlates of Cigarette Use Among Recent U.S. Veterans

Acheson

Straits-Tröster

Calhoun

et al. 2011

Military Psychology

View full text Add to dashboard Cite

Little is known about the smoking habits and cessation efforts of veterans returning from Iraq and Afghanistan, many of whom will seek health care services in the public sector. This project documents rates of smoking and quit attempts among veterans receiving Veteran's Health Administration (VHA) health care and describes the relationship between current smoking use/cessation and demographic characteristics, quality of life, and potential alcohol misuse.A large representative sample of Iraq/Afghanistan era veterans was surveyed using the VA Survey of Healthcare Experiences of Patients (Wright, Craig, Campbell, Schafer, & Humble, 2006). One third of respondents reported smoking during the past year and 24% reported currently smoking. Current smoking status was more prevalent among those who reported less education and lower household income. Current smoking status was also related to lower mental and physical health quality of life and higher potential alcohol misuse scores. Quit attempts were significantly less common among reserve component veterans and quitters reported higher incomes and were slightly older. The frequency of cigarette smoking among recent Correspondence should be addressed to Shawn K. Acheson, Durham VAMC, Rm. 24, Bldg. 16,

show abstract

“…The increase in nicotine self-administration could be a compensatory response to a reduction in nicotine reward after low doses of bupropion. In humans, the majority of studies have demonstrated that bupropion is more effective at improving smoking cessation than placebo [135, 136] . Bupropion has also been reported to reduce nicotine abstinence-associated depression, difficulty concentrating, and irritability, relative to placebo [137] .…”

Section: Ach-based Medication Developmentmentioning

confidence: 99%

Mechanism-based medication development for the treatment of nicotine dependence

Spiller

Gardner

2009

Acta Pharmacol Sin

View full text Add to dashboard Cite

Tobacco use is a global problem with serious health consequences. Though some treatment options exist, there remains a great need for new effective pharmacotherapies to aid smokers in maintaining long-term abstinence. In the present article, we first discuss the neural mechanisms underlying nicotine reward, and then review various mechanism-based pharmacological agents for the treatment of nicotine dependence. An oversimplified hypothesis of addiction to tobacco is that nicotine is the major addictive component of tobacco. Nicotine binds to α4β2 and α7 nicotinic acetylcholine receptors (nAChRs) located on dopaminergic, glutamatergic and GABAergic neurons in the mesolimbic dopamine (DA) system, which causes an increase in extracellular DA in the nucleus accumbens (NAc). That increase in DA reinforces tobacco use, particularly during the acquisition phase. Enhanced glutamate transmission to DA neurons in the ventral tegmental area appears to play an important role in this process. In addition, chronic nicotine treatment increases endocannabinoid levels in the mesolimbic DA system, which indirectly modulates NAc DA release and nicotine reward. Accordingly, pharmacological agents that target brain acetylcholine, DA, glutamate, GABA, or endocannabonoid signaling systems have been proposed to interrupt nicotine action. Furthermore, pharmacokinetic strategies that alter plasma nicotine availability, metabolism and clearance also significantly alter nicotine's action in the brain. Progress using these pharmacodynamic and pharmacokinetic agents is reviewed. For drugs in each category, we discuss the mechanistic rationale for their potential anti-nicotine efficacy, major findings in preclinical and clinical studies, and future research directions.

show abstract

Trends in smoking-related diseases

Cited by 34 publications

References 20 publications

Prevalence of Chronic Sputum and Associated Factors in Korean Adults

Prevalence of Chronic Sputum and Associated Factors in Korean Adults

Characteristics and Correlates of Cigarette Use Among Recent U.S. Veterans

Mechanism-based medication development for the treatment of nicotine dependence

Contact Info

Product

Resources

About